Posts by VIVA! Communications
Promising vaccination that lowers cholesterol could prevent heart attacks
A promising new vaccination that is designed to prevent heart attacks is currently being developed by Austrian biotech company, AFFiRis. The research has shown that the injection can be targeted towards the immune system to lower cholesterol by stopping fatty deposits from clogging the arteries and reducing the risk of heart disease. The vaccine, known…
Read MoreQueensland to bolster its biomedical industry with $4m injection
Addressing the BIO conference in San Diego on Monday, (June 19, 2017) QLD Premier, Annastacia Palaszczuk announced the launch of the Queensland Biomedical 10-Year Roadmap and Action Plan, which aims to bolster the QLD economy by upwards of AUD$2 billion by investing in biomedical sciences. A press release issued by the Premier’s office explains that…
Read MoreGround-breaking test developed in prostate cancer treatment
Scientists have this week announced an exciting new development in prostate cancer therapy with the news that a ground-breaking blood test can now monitor DNA to see if patients are responding to treatment. The test will enable doctors to check whether precision drugs are working and, if not, switch patients to a different treatment in…
Read MoreBe a ‘bloody legend’ & donate – only two donations a year could generate near endless blood supply
This week (June 11-17) marks the Australian Red Cross National Blood Donor Week 2017 and Australians are being urged to donate blood twice a year to generate a near-endless blood supply. Speaking with Hot FM on QLD’s Sunshine Coast, Australian Red Cross spokesperson, Jennifer Campbell Case explained only a small number of Australian’s regularly donate…
Read MoreAustralian biotech company shares hit record high
Major Australian biotechnology company, CSL has secured a foothold in the world’s fastest growing plasma therapeutics market with a $US352 million ($466m) stake in Chinese biotech Ruide (Wuhan Zhong Yuan Rui De Biologics). This purchase of an 80 per cent stake provides CSL with a strategic presence in China’s plasma product market, which was valued…
Read More